[1]
|
H. Caldas, L. E. Honsey and R. A. Altura. (2005) Survivin a novel Survivin splice variant expressed in malignancies. Mol Cancer, 4(1): 11-23.
|
[2]
|
W. Salz, D. Eisenberg and J. Plescia. (2005) A survivin gene signature predicts aggressive tumor behavior. Cancer Res, 65: 3531-3534.
|
[3]
|
T. Liu and D. Grossman. (2004) Rapid induction of mitochondria events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene, 23 (1): 39-48.
|
[4]
|
M. Stevenson. (2004) Therapeutic potential of RNA interference. N Engl J Med, 351 (17): 1772-1777.
|
[5]
|
D. C. Altieri; (2003) Survivin versatile modulation of cell division and apoptosis in cancer. Oncogene, 22: 8581–8589.
|
[6]
|
X. Ling, R. J. Bernacki, M. G. Brattain and F. Li. (2004) Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem; 279: (5)196-203.
|
[7]
|
C. D. Novina and P. A. Sharp. (2004) The RNAi revolution. Na-ture, 430(6996): 161-164.
|
[8]
|
P. D. Zamore. (2002) Ancient pathways p rogrammed by small RNAs. Science, 296 (5571): 1265-1269.
|
[9]
|
G. J. Hannon. (2002) RNA interference. Nature, 418: 2442-2511.
|
[10]
|
M. Pennati, M. Binda, M. De Cesare, G. Pratesi, M. Folini, L. Citti, M. G. Daidone, F. Zunino and N. Zaffaroni. (2004) Ri-bozyme-mediated down-regulation of survivin expression sensi-tizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis; 25: 1129-1136.
|
[11]
|
M. Izquierdo. (2005) Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther, 12: 217-227.
|
[12]
|
M. Kappler, M. Bache, F. Bartel, M. Kotzsch, M. Panian, P. Wurl, K. Blumke, H. Schmidt, A. Meye and H. Taubert. (2004) Knock-down of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independ-ently of p53. Cancer Gene Ther, 11: 186-193.
|
[13]
|
M .Kappler, H. Taubert, F. Bartel, K. Blumke, M. Panian, H. Schmidt, J. Dunst and M. Bache. (2005) Radiosensitization, after a combinedtreatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wtp53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep, 13: 167-172.
|
[14]
|
M. Chawla-Sarkar, S. I. Bae, F. J. Reu, B. S. Jacobs, D. J. Lindner and E. C. Borden. (2004) Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ, 11: 915-923.
|
[15]
|
S. Coma, V. Noe, C. Lavarino, J. Adan, M. Rivas, M. Lo-pez-Matas, R. Pagan, F. Mitjans, S. Vilaro, J. Piulats and C. J. Ciudad; (2004) Use of siRNAs and antisense oligonucleo -tides against survivin RNA to inhibit steps leading to tumor angiogene-sis. Oligonucleotides, 14: 100-113.
|
[16]
|
S. M. Elbashir, W. Lendeckel and T. Tuschl. (2002) RNA inter-ference is mediated by 21-and 22-nucleotide RNAs. Genes Dev, 15: 188-200.
|
[17]
|
Corresponding author; Prof. Xi Tao, Research Centre of Biotech- nology, China Pharmaceutical University, NanJing, 210009, China
|